# US 2010/0063040 A1 · Sulfonamide Derivative Having PGD2 Receptor Antagonistic Activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0063040 A1
- Document ID: US20100063040A1
- Status: Published application
- Kind: A1
- Application number: 11/992,602
- Filed: 2006-09-25
- Published: 2010-03-11
- Earliest claimed: 2005-09-27
- Assignees: Shionogi & Co., Ltd.
- Inventors: Akira Kugimiya
- Web page: https://patentgrep.com/patent/US20100063040A1

## CPC

- C07D 295/26: Sulfur atoms
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/20: Hypnotics; Sedatives
- A61P 27/02: Ophthalmic agents
- A61P 27/14: Decongestants or antiallergics
- A61P 27/16: Otologicals
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/12: Schistosomicides
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 207/14: Nitrogen atoms not forming part of a nitro radical
- C07D 207/48: Sulfur atoms
- C07D 211/58: attached in position 4
- C07D 211/70: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 211/96: Sulfur atom
- C07D 213/38: having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C07D 213/40: Acylated substituent nitrogen atom
- C07D 213/64: attached in position 2 or 6
- C07D 213/71: to which a second hetero atom is attached
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 231/40: Acylated on said nitrogen atom
- C07D 235/08: Radicals containing only hydrogen and carbon atoms
- C07D 235/30: Nitrogen atoms not forming part of a nitro radical
- C07D 235/32: Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
- C07D 243/08: not condensed with other rings
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 261/18: Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C07D 263/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 263/58: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D 265/36: condensed with one six-membered ring
- C07D 271/10: 1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D 277/24: Radicals substituted by oxygen atoms
- C07D 277/28: Radicals substituted by nitrogen atoms
- C07D 285/12: 1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D 285/135: Nitrogen atoms
- C07D 295/096: with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/155: with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 307/42: Singly bound oxygen atoms
- C07D 307/52: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 307/56: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 307/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 333/36: Nitrogen atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides an sulfonamide derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A compound of the general formula (II): wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a nitrogen-containing non-aromatic heterocyclic ring etc.; the ring C is an aromatic carbocyclic ring etc.; R1 is carboxy etc.; R2 is independently a halogen atom etc.; R3 is optionally substituted alkyloxy etc.; R4 is independently a halogen atom etc.; R5 is independently optionally substituted alkyl etc.; M is sulfonyl etc.; Y is a single bond etc.; L1 is a single bond etc.; L2 is a single bond etc.; k is 0, 1, 2, 3 or 4; n is 0, 1 or 2; and q is 0, 1, 2 or 3; provided that a) k is not 0 when the ring B is a 6-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s) and the ring C is a benzene ring, etc.; a pharmaceutically acceptable salt or a hydrate thereof.

## Claims

### Claim 1

A PGD2 receptor antagonist comprising a compound of the general formula (I):
wherein the ring A is an aromatic carbocyclic ring or an aromatic heterocyclic ring;
the ring B is a nitrogen-containing non-aromatic heterocyclic ring or a nitrogen-containing aromatic heterocyclic ring;
the ring C is an aromatic carbocyclic ring or an aromatic heterocyclic ring;
R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, or a carboxy equivalent;
R2 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group;
R3 is a hydrogen atom, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted cycloalkylthio, optionally substituted cycloalkenylthio, optionally substituted arylthio or optionally substituted heteroarylthio;
R4 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group;
R5 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, oxo, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group;
M is carbonyl or sulfonyl;
Y is a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), an oxygen atom, a sulfur atom or —N(R6)—;
L1, L2 and L3 are independently a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatom(s), optionally substituted alkynylene optionally containing one or two heteroatom(s) or —N(R7)—;
R6 and R7 are independently a hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group;
k is 0, 1, 2, 3 or 4;
n is 0, 1 or 2; and
q is 0, 1, 2 or 3; provided that a) k is not 0 when the ring B is a 6-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s), and the ring C is a benzene ring, b) the ring C is not an indole ring or an azaindole ring, c) R1 is not carboxy when the ring C is a benzene ring, -L3- is —(O-alkylene)-, and the substituting position of L3 and Y is an ortho-position each other in the ring C, and d) the substituting position of L3 and Y is not a para-position in the ring C when the ring B is a thiazolidine ring and the ring C is a benzene ring;
a pharmaceutically acceptable salt or solvate thereof as an active ingredient.

### Claim 2 (depends on 1)

A PGD2 receptor antagonist according to claim 1, wherein M is sulfonyl, L1 is a single bond and L2 is a single bond.

### Claim 3 (depends on 1)

A PGD2 receptor antagonist according to claim 1, which is a therapeutic agent for allergy.

### Claim 4 (depends on 1)

A PGD2 receptor antagonist according to claim 1, which is a therapeutic agent for asthma.

### Claim 5

A compound of the general formula (II):
wherein the ring A is an aromatic carbocyclic ring or an aromatic heterocyclic ring;
the ring B is a nitrogen-containing non-aromatic heterocyclic ring or a nitrogen-containing aromatic heterocyclic ring;
the ring C is an aromatic carbocyclic ring or an aromatic heterocyclic ring;
R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, or a carboxy equivalent;
R2 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group;
R3 is a hydrogen atoms, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted cycloalkylthio, optionally substituted cycloalkenylthio, optionally substituted arylthio or optionally substituted heteroarylthio;
R4 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group;
R5 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, oxo, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted non-aromatic heterocyclic group;
M is carbonyl or sulfonyl;
Y is a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), an oxygen atom, a sulfur atom or —N(R6)—;
L1, L2 and L3 are independently a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatom(s), optionally substituted alkynylene optionally containing one or two heteroatom(s) or —N(R7)—;
R6 and R7 are independently a hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group;
k is 0, 1, 2, 3 or 4;
n is 0, 1 or 2; and
q is 0, 1, 2 or 3; provided that a) k is not 0 when the ring B is a 6-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s), and the ring C is a benzene ring, b) the ring C is not an indole ring or an azaindole ring, c) Y, L1 and L2 are single bonds, the ring B is a piperazine ring and R3 is C2-C4 alkyloxy when the ring C is a benzene ring, -L3- is —(O-alkylene)-, the substituting position of L3 and Y is an ortho-position each other in the ring C and R1 is carboxy, d) the substituting position of L3 and Y is not a para-position in the ring C when the ring B is a thiazolidine ring and the ring C is a benzene ring, and e) the group of the formula of
is not a group of the formula of
when the ring C is a benzene ring, -L3- is —(O-alkylene)- and the substituting position of L3 and Y is a para-position in the ring C, and f) the ring B is not a diazepindione ring;
a pharmaceutically acceptable salt or solvate thereof.

### Claim 6 (depends on 5)

A compound according to claim 5, wherein M is sulfonyl;
a pharmaceutically acceptable salt or solvate thereof.

### Claim 7

A compound of the general formula (III):
wherein the ring D is a benzene ring, a naphthalene ring, a 2-pyridone ring, a pyridine ring, a benzoxazolone ring, a benzoxadinone ring or a benzimidazole ring;
R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, or a carboxy equivalent;
R2 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group;
R3 is optionally substituted C1-C6 alkyloxy, optionally substituted C2-C6 alkenyloxy, optionally substituted C2-C6 alkynyloxy, optionally substituted C3-C6 cycloalkyloxy, optionally substituted C3-C6 cycloalkenyloxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted C1-C6 alkylthio, optionally substituted C2-C6 alkenylthio, optionally substituted C2-C6 alkynylthio, optionally substituted C3-C6 cycloalkylthio, optionally substituted C3-C6 cycloalkenylthio, optionally substituted arylthio or optionally substituted heteroarylthio;
R4 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or optionally substituted non-aromatic heterocyclic group;
R5 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, oxo, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group;
M is carbonyl or sulfonyl;
L3 is independently a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatom(s), optionally substituted alkynylene optionally containing one or two heteroatom(s) or —N(R7)—;
R7 is hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group;
Y is a single bond or optionally substituted alkylene optionally containing one or two heteroatom(s);
Z is CH, C(R4) or N;
n is 0, 1 or 2;
p s 1, 2, 3 or 4; and
q is 0, 1, 2 or 3; provided that R1 is not carboxy when the ring D is a benzene ring, -L3- is —(O-alkylene)-, and the substituting position of L3 and Y is an ortho-position in the ring D;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 8 (depends on 7)

A compound according to claim 7, wherein R1 is carboxy and -L3- is —(O- optionally substituted alkylene)-;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 9 (depends on 7)

A compound according to claim 7, wherein the ring D is a benzene ring or a pyridine ring;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 10 (depends on 7)

A compound according to claim 7, wherein R3 is optionally substituted C1-C6 alkyloxy or optionally substituted C1-C6 alkylthio;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 11 (depends on 7)

A compound according to claim 7, wherein M is sulfonyl;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 12 (depends on 7)

A compound according to claim 7, wherein Y is a single bond;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 13 (depends on 7)

A compound according to claim 7, wherein R2 is a halogen atom, optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl or a non-aromatic heterocyclic ring, and p is 1 or 2;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 14 (depends on 7)

A compound according to claim 7, wherein R2 is a halogen atom, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl or a non-aromatic heterocyclic ring, and p is 1 or 2;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 15 (depends on 7)

A compound according to claim 7, wherein R4 is a halogen atom, optionally substituted alkyl or optionally substituted alkyloxy, and q is 0 or 1;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 16 (depends on 7)

A compound according to claim 7, wherein the substituting position between Y and L3 is a meta-position in the ring D;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 17

A compound of the general formula (IV):
wherein the ring D is a benzene ring, a naphthalene ring, a 2-pyridone ring, a pyridine ring, a benzoxazolone ring, a benzoxadinone ring or a benzimidazole ring;
the ring E is a ring of the formula of
R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, or a carboxy equivalent;
R2 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group;
R3 is optionally substituted C1-C6 alkyloxy, optionally substituted C2-C6 alkenyloxy, optionally substituted C2-C6 alkynyloxy, optionally substituted C3-C6 cycloalkyloxy, optionally substituted C3-C6 cycloalkenyloxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted C1-C6 alkylthio, optionally substituted C2-C6 alkenylthio, optionally substituted C2-C6 alkynylthio, optionally substituted C3-C6 cycloalkylthio, optionally substituted C3-C6 cycloalkenylthio, optionally substituted arylthio or optionally substituted heteroarylthio;
R4 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group;
R5 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, oxo, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group;
M is carbonyl or sulfonyl;
L3 is independently a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatom(s), optionally substituted alkynylene optionally containing one or two heteroatom(s) or —N(R7)—;
R7 is hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group,
Y is a single bond or optionally substituted alkylene optionally containing one or two heteroatom(s);
Z is CH, C(R4) or N;
n is 0, 1 or 2;
p is 1, 2, 3 or 4; and
q is 0, 1, 2 or 3; provided that a) R1 is not carboxy when the ring D is a benzene ring, -L3- is —(O-alkylene)-, and the substituting position of L3 and Y is an ortho-position in the ring D, b) the group of the formula of
is not a group of the formula of
when the ring D is a benzene ring, -L3- is —(O-alkylene)-, and the substituting position of L3 and Y is a para-position in the ring D;
a pharmaceutically acceptable salt or solvate thereof.

### Claim 18 (depends on 17)

A compound according to claim 17, wherein R1 is carboxy and -L3- is —(O— optionally substituted alkylene)-;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 19 (depends on 17)

A compound according to claim 17, wherein the ring D is a benzene ring or a pyridine ring;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 20 (depends on 17)

A compound according to claim 17, wherein R3 is optionally substituted C1-C6 alkyloxy or optionally substituted C1-C6 alkylthio;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 21 (depends on 17)

A compound according to claim 17, wherein M is sulfonyl;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 22 (depends on 17)

A compound according to claim 17, wherein Y is a single bond;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 23 (depends on 17)

A compound according to claim 17, wherein R2 is a halogen atom, optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl or a non-aromatic heterocyclic ring, and p is 1 or 2;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 24 (depends on 17)

A compound according to claim 17, wherein R2 is a halogen atom, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl or a non-aromatic heterocyclic ring, and p is 1 or 2;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 25 (depends on 17)

A compound according to claim 17, wherein R4 is a halogen atom, optionally substituted alkyl, optionally substituted alkyloxy, and q is 0 or 1;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 26 (depends on 17)

A compound according to claim 17, wherein the substituting position between Y and L3 is a meta-position in the ring D;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 27 (depends on 5)

A pharmaceutical composition comprising a compound according to claim 5, a pharmaceutically acceptable salt or hydrate thereof as an active ingredient.

### Claim 28 (depends on 27)

A pharmaceutical composition of claim 27, which is a DP receptor antagonist.

### Claim 29 (depends on 27)

A pharmaceutical composition of claim 27, which is a therapeutic agent for allergy.

### Claim 30 (depends on 29)

A pharmaceutical composition of claim 29, wherein the therapeutic agent for allergy is a therapeutic agent for asthma.

### Claim 31 (depends on 5)

A method for treating a disease related to DP receptor characterized by administration of the compound of claim 5, pharmaceutically acceptable salt or solvate thereof.

### Claim 32 (depends on 31)

A method according to claim 31, wherein the disease related to DP receptor is asthma.

### Claim 33 (depends on 5)

Use of the compound of claim 5, pharmaceutically acceptable salt or solvate thereof in the manufacturing of a therapeutic agent for treating a disease related to DP receptor.

### Claim 34 (depends on 32)

Use of the compound of claim 32, pharmaceutically acceptable salt or solvate thereof, wherein the disease related to DP receptor is asthma

### Claim 35

A compound of the general formula (V):
wherein the ring D is a benzene ring, a naphthalene ring, a 2-pyridone ring, a pyridine ring, a benzoxazolone ring, a benzoxadinone ring or a benzimidazole ring;
R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, or a carboxy equivalent;
R2 is independently a hydrogen atoms, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group;
R8 is a halogen atom, trifluoromethanesulfonyloxy or piperazino;
L3 is independently a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatom(s), optionally substituted alkynylene optionally containing one or two heteroatom(s) or —N(R7)—;
R7 is independently a hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; and
p is 1, 2, 3 or 4; provided that the substituting position of the piperidino group and L3 each other is not an ortho-position in the ring D when the ring D is a benzene ring and -L3- is —(O-alkylene)-;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 36 (depends on 35)

A compound according to claim 35, wherein the ring D is a benzene ring and R8 is a halogen atom;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 37 (depends on 35)

A compound according to claim 35, wherein the ring D is a benzene ring and R8 is piperazino;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 38 (depends on 35)

A compound according to claim 35, wherein R1 is carboxy or alkyloxycarbonyl and -L3- is —(O-methylene)-;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 39 (depends on 35)

A compound according to claim 35, wherein R2 is a halogen atom, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl, an optionally substituted non-aromatic heterocyclic ring, and p is 1 or 2;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 40 (depends on 35)

A compound according to claim 35, wherein the substituting position between R8 and L3 in the ring D is a meta-position;
a pharmaceutically acceptable salt or hydrate thereof.

### Claim 41 (depends on 7)

A pharmaceutical composition comprising a compound according to claim 7, a pharmaceutically acceptable salt or hydrate thereof as an active ingredient.

### Claim 42 (depends on 17)

A pharmaceutical composition comprising a compound according to claim 17, a pharmaceutically acceptable salt or hydrate thereof as an active ingredient.

### Claim 43 (depends on 7)

A method for treating a disease related to DP receptor characterized by administration of the compound of claim 7, pharmaceutically acceptable salt or solvate thereof.

### Claim 44 (depends on 17)

A method for treating a disease related to DP receptor characterized by administration of the compound of claim 17, pharmaceutically acceptable salt or solvate thereof.
